Breaking News


Twice-weekly treatment with topical tacrolimus in patients with moderate-severe atopic dermatitis: a post hoc analysis of two trials


A post hoc analysis of two 1-year multicenter, randomized, phase III trials (one in adults, one in children) with moderate-severe atopic dermatitis (AD) was conducted. The trials evaluated tacrolimus ointment (0.1% in adults, 0.03% in children) and comprised an open-label phase (OLP) of 1-6 weeks until a score of 2 or less on the Investigator Global Assessment (IGA) was achieved. Patients then entered a 12-month, double-blind, vehicle-controlled disease-control period (DCP). If a flare occurred, patients were treated in an OLP phase of 1-6 weeks until an IGA of 2 or less was achieved; if the flare lasted longer than 6 weeks the patient was withdrawn. Twice-weekly treatment with tacrolimus ointment significantly ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list